- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 779855 [Title] => Novartis, NKTI tie up to help GEP NET patients [Summary] =>Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.
[DatePublished] => 2012-02-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 464588 [Title] => Reducing risk of cancer returning in patients [Summary] =>MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.
[DatePublished] => 2009-05-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
NOVARTIS ONCOLOGY
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 779855 [Title] => Novartis, NKTI tie up to help GEP NET patients [Summary] =>Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.
[DatePublished] => 2012-02-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 464588 [Title] => Reducing risk of cancer returning in patients [Summary] =>MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.
[DatePublished] => 2009-05-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
EZ2 - 26 14
SUERTRES - 2 0 8
6/49 Lotto - 12 35 16 7 45 42
P15,840,000.00
6/58 Ultra Lotto - 36 46 16 19 23 27
P314,591,291.00
- 12:00 am